'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer

Voskoboynik, Mark, Staffurth, John Nicholas ORCID: https://orcid.org/0000-0002-7834-3172, Malik, Zafar, Sweeney, Christopher and Chowdhury, Simon 2014. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Review of Anticancer Therapy 14 (11) , pp. 1253-1256. 10.1586/14737140.2014.971112

Full text not available from this repository.

Abstract

Docetaxel has an established role in the treatment of metastatic castrate-resistant prostate cancer. A number of recent treatments have been shown to improve the survival outcomes for this group of patients and many with improved toxicity profiles, bringing the role of docetaxel into question. We discuss the results and implications of the CHAARTED study that demonstrated a significant improvement in overall survival with docetaxel in metastatic hormone-sensitive prostate cancer.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher:	Taylor and Francis
ISSN:	1473-7140
Last Modified:	31 Oct 2022 09:01
URI:	https://orca.cardiff.ac.uk/id/eprint/79562

Citation Data

Cited 11 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item